Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 415

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1A
Chunk 415
---
 in us and thus may influence certain
actions requiring stockholder vote.

Risks
Related to Our Intellectual Property

We
depend on rights to Telomir-1 that are or will be licensed to us. We do not own the intellectual property rights to Telomir-1 and any
loss of our rights to it could prevent us from selling our product.

Within
our present and future pipeline of treatments, Telomir-1 is in-licensed from another company. We do not currently own any intellectual
property rights, including the patent application that underlies this license. Our rights to use Telomir-1 is subject to the negotiation
of, continuation of and compliance with the terms of this license. Thus, the non-provisional patent application is not written by us
or our attorneys, and we did not have control over the drafting and prosecution. The patent owner and our licensor might not have given
the same attention to the drafting and prosecution of these patents and applications as we would have if we had been the owner of the
patent application and had control over the drafting. We cannot be certain that drafting of the licensed patent application, or patent
prosecution, by the licensor have been or will be conducted in compliance with applicable laws and regulations or will result in valid
and enforceable patents and other intellectual property rights. This absence of control over the drafting, prosecution of patent and
applications, along with non-compliance with royalty payments and confidentiality breaches are just some of the ways that may result
in the Company’s’ loss of the license and inability to continue operations.

Significant
additional research and development activity, pre-clinical testing, and/or clinical testing Telomir-1 is required before we will have
a chance to achieve a viable product for licensing or commercialization. Our business currently depends entirely on the successful development,
regulatory approval, and licensing or commercialization of our product candidate, which may never occur.

Enforcement
of our licensed patent application or defense of any claims asserting invalidity of these patents is often subject to the control or
cooperation of our licensor. Legal action could be initiated against the owners of the intellectual property that we license and an adverse
outcome in such legal action could harm our business because it might prevent such companies or institutions from continuing to license
intellectual property that we may need to operate our business. In addition, such licensor may resolve such litigation in a way that
benefits it but adversely affects our ability to